Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Genentech Inc.
Keeping Track: Clarus, Agile and Sunovion Look To Bounce Back From CRLs; FDA To Review Rituximab Biosimilar
The latest drug development news and highlights from our US FDA Performance Tracker.
Genmab Fails To Convince CHMP Of Case For Maintenance Arzerra
The anti-CD20 monoclonal antibody Arzerra (ofatumumab) has not been recommended for the maintenance therapy of relapsed chronic lymphocytic leukemia (CLL), an expanded indication, by the Committee for Medicinal Products for Human Use (CHMP).
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice